Atypical femoral shaft fracture in a patient with nonmetastatic prostate cancer on zoledronic acid therapy: Effect of therapy or coincidence?

Singapore Medical Journal

Volumn 53, Issue 3, 2012, Pages

  Reddy, S V B ^a   Gupta, S K ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Atypical; Diphosphonates; Femoral shaft; Fracture; Prostate cancer

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; PARATHYROID HORMONE[1-34]; ZOLEDRONIC ACID;

AGED; ARTICLE; BED REST; BONE DENSITY; CASE REPORT; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR SHAFT FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; FOLLOW UP; HUMAN; INTRAMEDULLARY NAILING; MALE; OSTEOPOROSIS; PAIN; PROSTATE CANCER; X RAY FILM;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMORAL FRACTURES; FOLLOW-UP STUDIES; FRACTURE FIXATION, INTRAMEDULLARY; FRACTURE HEALING; FRACTURES, SPONTANEOUS; HUMANS; IMIDAZOLES; MALE; NEOPLASM STAGING; ORCHIECTOMY; OSTEOPOROSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 84863256516     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Pazianas M, Cooper C, Ebetino FH, Russell RG. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 2010; 6:325-343.
2. Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med 2010; 363:2027-2035.
3. Israeli RS. Managing bone loss and bone metastases in prostate cancer patients: a focus on bisphosphonate therapy. Rev Urol 2008; 10:99-110.
4. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007; 89:349-353.
5. Ing-Lorenzini K, Desmeules J, Plachta O, et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 2009; 32:775-785.
6. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008; 358:1304-1306.
7. Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf) 2010; 72:161-168.
8. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25:2267-2294.
9. Wernecke G, Namduri S, DiCarlo EF, Schneider R, Lane J. Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on longterm pamidronate and zoledronic acid. HSS J 2008; 4:123-127.
10. Kwek EB, Koh JS, Howe TS. More on atypical fractures of the femoral diaphysis. N Engl J Med 2008; 359:316-317.
11. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90:1294-1301.
12. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010; 362:1761-1771.
13. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009; 24:1095-1102.
14. Endocrine Society Statement. The Endocrine Society Statement on longterm use of bisphosphonates, March 12, 2010 [online]. Available at: www.endo-society.org. Accessed August 23, 2010.